A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO

Intervention/treatment:
RITLECITINIB (PF-06651600) / BREPOCITINIB (PF-06700841)
Medical condition:
VITILIGO
Protocol code:
B7981019
Control number:
221229
Status:
Closed
Approved:
November 21, 2018
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03715829
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA ULC

Locations

British Columbia

Dr. Chih-ho Hong Medical Inc.
Surrey, British Columbia, V3R 6A7
Enverus Medical Research
Surrey, British Columbia, V3V 0C6
University of British Columbia
Vancouver, British Columbia, V5Z 4E8

Manitoba

Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, R3M 3Z4

Ontario

CCA Medical Research
Ajax, Ontario, L1S 7K8
DermEdge Research
Mississauga, Ontario, L5H 1G9
Guenther Research Inc.
London, Ontario, N6A 3H7
K.Papp Clinical Research
Waterloo, Ontario, N2J 1C4
Lynderm Research Inc.
Markham, Ontario, L3P 1X3
North York Research Inc.
North York, Ontario, M2M 4J5
The Centre for Clinical Trials
Oakville, Ontario, L6J 7W5
The Centre for Dermatology
Richmond Hill, Ontario, L4B 1A5

Quebec

Centre de Recherche Dermatologique du Quebec metropolitain (CRDQ)
Québec, Quebec, G1V 4X7
Centre de Recherche Saint-Louis
Québec, Quebec, G1W 4R4
Centre de Recherche Saint-Louis
Québec, Quebec, G1W1S2
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1L 0H8
Innovaderm Research Inc.
Montreal, Quebec, H2X 2V1

Results

See the results from the trial NCT03715829. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?